Does bilateral family history increase Alzheimer’s susceptibility without diagnosing the patient?

Family history is relevant to this 74-year-old woman’s Alzheimer risk assessment, but it cannot diagnose Alzheimer disease in her. The claim is largely sound: the risk implication is plausible, whereas the limit on diagnostic inference is well established.

Familial susceptibility

• Alzheimer disease in close relatives is associated with increased familial risk. In a Utah genealogy-linked cohort, risk was 1.73-fold higher with ≥1 affected first-degree relative and 3.98-fold higher with ≥2 affected first-degree relatives, supporting a dose–response relationship with affected-family burden.
• A history on both maternal and paternal sides plausibly reflects a greater aggregate burden of risk factors, especially if relatives were first-degree, numerous, or developed dementia relatively early. However, studies do not quantify an independent excess risk specifically attributable to bilateral lineage history versus one-sided history after accounting for number of affected relatives and shared exposures.
• Familial aggregation can reflect APOE ε4, other inherited variants, and shared environmental/social factors. APOE ε4 increases susceptibility but is not deterministic; family history alone cannot distinguish genetic from non-genetic contributions.

Pathology and diagnostic implications

• A relative’s reported Alzheimer diagnosis—even if credible—does not establish this patient’s cause of cognitive symptoms or underlying pathology. Under the NIA-AA AT(N) framework, Alzheimer disease biologically requires abnormal amyloid (A) and tau (T) biomarkers; neurodegeneration markers assist staging but are not disease-specific.
• Unverified family diagnoses are particularly unreliable. Family-informant classification had 69% sensitivity and 73% specificity versus neuropathology, with non-Alzheimer dementias and stroke contributing to error.
• In an appropriate clinical evaluation, family history should inform history-taking and possible genetic counseling, not substitute for cognitive assessment, laboratory evaluation, structural imaging, or—when diagnostically appropriate—CSF amyloid/tau testing or amyloid PET.

Bottom line

• Bilateral family history plausibly increases familial susceptibility, chiefly as a marker of greater affected-relative burden, but it cannot determine this woman’s individual Alzheimer pathology; patient-specific clinical and biomarker evidence is required.